Released Nov 13, 2026, after the close
10-Q filed Nov 13, 2026, 44 days after period end · 0001683168-26-008697
Q3 2026 · 10-Q
Revenue—
Net Income-$3.42M-$3.42M N/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.14-$0.14 N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$3,439,087N/M
Operating Cash Flowderived-$2,950,806N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$3.42M | -$5.41M | -$5.97M | -$6.34M |
| EPS Diluted | -$0.14 | -$0.25 | -$0.55 | -$4.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR